肾移植受者接种流感疫苗后带状疱疹风险评估
本研究基于台湾全民健康保险研究数据库2008至2017年数据,采用基于人群的回顾性自身对照病例系列设计,纳入4222例接种流感疫苗的肾移植受者,其中67例在接种前后6个月内诊断带状疱疹。接种后15天和30天风险间隔的带状疱疹发病率比与对照间隔相比均无统计学显著升高,结论为未发现流感疫苗与带状疱疹风险升高存在显著关联。
要点
- 肾移植受者接种流感疫苗后15天带状疱疹发病率比IRR=0.63(95%CI 0.23-1.89),无统计学显著升高。
- 接种后30天带状疱疹发病率比IRR=1.50(95%CI 0.71-3.16),无统计学显著升高。
- 按年龄、性别及基础疾病分层后,发病率比均无统计学显著差异。
核心结论
- 未检测到流感疫苗与带状疱疹风险升高之间存在显著关联。
- 每年接种流感疫苗对肾移植受者似乎是合理的做法。
研究设计与样本
- 研究设计为基于人群的回顾性自身对照病例系列。
- 数据来源于台湾全民健康保险研究数据库,时间跨度为2008年至2017年。
- 纳入接种流感疫苗前后6个月内诊断带状疱疹的肾移植受者,共4222例接种疫苗的肾移植受者,其中67例随后诊断为带状疱疹。
- 定义接种后最初15天和30天为风险间隔,其余所有时期为对照间隔。
主要发现
- 接种流感疫苗后最初15天带状疱疹发病率比IRR=0.63(95%CI 0.23-1.89),与暴露后观察时间相比无统计学显著升高。
- 接种后最初30天带状疱疹发病率比IRR=1.50(95%CI 0.71-3.16),与暴露后观察时间相比无统计学显著升高。
- 与暴露前观察时间相比,上述发病率比结果类似。
- 按年龄、性别和基础疾病(包括癌症和自身免疫性疾病)分层的亚组分析显示,发病率比无统计学显著差异。
关键数值与推荐
- 风险间隔为接种后最初15天和30天,对照间隔为所有其他时期。
- 主要效应量为发病率比IRR,接种后15天IRR=0.63(95%CI 0.23-1.89),30天IRR=1.50(95%CI 0.71-3.16)。
临床怎么用
- 作者认为,每年接种流感疫苗对肾移植受者似乎是合理的做法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Reactivation of the latent varicella-zoster virus can cause herpes zoster (HZ) infection, and renal transplant recipients undergoing immunosuppressive therapy are particularly susceptible to this condition. This study aims to evaluate the potential increase in HZ incidence following influenza vaccination among this specific patient population. METHODS: This study was a population-based, retrospective, self-controlled case series. Data were retrieved from Taiwan's National Health Insurance Research Database spanning the years 2008 to 2017. Patients diagnosed with HZ within a 6-month period before and after receiving the influenza vaccine were eligible for inclusion. Two distinct time intervals were defined for analysis: the initial 15 days and 30 days following vaccination were categorized as risk intervals, while all other periods served as control intervals. Incidence rate ratios (IRRs) were computed to compare HZ incidence during the risk intervals with that during the control intervals. RESULTS: This study encompassed a cohort of 4,222 renal transplant recipients who had received the influenza vaccine. Among this group, 67 recipients were subsequently diagnosed with HZ. The IRR during both the initial 15 days (IRR = 0.63; 95 % CI, 0.23-1.89) and the first 30 days (IRR = 1.50; 95 % CI, 0.71-3.16) following influenza vaccination did not demonstrate a statistically significant increase when compared to the post-exposure observation times. Comparable results were also observed when comparing these IRR values to the pre-exposure observation times. The subgroup analysis, stratified by age, sex, and underlying medical conditions (including cancer and autoimmune diseases), revealed that the IRRs did not exhibit statistically significant differences. CONCLUSIONS: No significant association between the influenza vaccine and an elevated risk of HZ was detected. The administration of annual influenza vaccines appears to be a reasonable practice for renal transplant recipients.
引用
- Cheng TM, Chen YS, Wei KC, et al. Assessment of the herpes zoster risk among renal transplant recipients administered the influenza vaccine. Vaccine. 2024. PMID: 38897892. doi:10.1016/j.vaccine.2024.06.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。